| Market Capitalization (Millions $) |
94 |
| Shares
Outstanding (Millions) |
120 |
| Employees |
29 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-53 |
| Cash Flow (TTM) (Millions $) |
-32 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Oncolytics Biotech Inc is a biopharmaceutical company that focuses on the development of oncolytic viruses for the treatment of cancer. Their primary product candidate is called Reolysin, which is a proprietary formulation of the human reovirus.
The company's approach involves using the reovirus to selectively target and kill cancer cells, while leaving healthy cells unharmed. This unique concept is based on the fact that certain cancer cells have an abnormal signaling pathway, which allows the reovirus to replicate within those cells and induce cell death.
Oncolytics Biotech conducts clinical trials to test the efficacy and safety of Reolysin in various types of cancer, including breast, lung, and pancreatic cancer. The company also collaborates with other pharmaceutical companies to investigate combination therapies and expand the potential of their oncolytic virus technology.
In addition to Reolysin, Oncolytics Biotech also has a pipeline of other oncolytic virus candidates under development for the treatment of different types of cancer. Their goal is to offer new and innovative treatment options for patients with limited therapeutic alternatives.
Overall, Oncolytics Biotech Inc is a biopharmaceutical company dedicated to developing oncolytic viruses as a novel approach to fighting cancer, with the aim of improving patient outcomes and quality of life.
Company Address: 4350 Executive Drive San Diego 92121 CA
Company Phone Number: 670-7377 Stock Exchange / Ticker: NASDAQ ONCY
|
2.01%